Previously treated patients (EGFR-TKI or platinum-based chemotherapy) with locally advanced or metastatic NSCLC with EGFR-activating mutations (exon 19 deletion or L858R). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.